如何有效评估降压治疗依从性，如何干预以改善依从性？

参考文献

[1] World Health Organization . Adherence to long—term therapies: evidence for action[M]. Geneva: WHO, 2003: 1-212.

[2] 高血压药物治疗依从性共识修订联合专家委员会 . 提高高血压患者药物治疗依从性和改善血压控制中国专家共识[J]. 中华高血压杂志 (中英文)， 2024， 32（3）： 205-213.

[3] Mahmood S, Jalal Z, Hadi MA, et al. Prevalence of non—adherence to antihypertensive medication in Asia: a systematic review and meta—analysis[J]. Int J Clin Pharm， 2021， 43（3）： 486-501.

[4] Tomaszewski M. OUTREACH — adherence to treatment and blood pressure control[C/OL]// ESC Congress 2025 together with World Congress of Cardiology, Madrid, 2025[2026—04—15]. https://esc365.escardio.org/ESC—Congress.

[5] Idir H, Vincent J, Pierre B, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients[J]. J Hypertens， 2017， 35（9）： 1891-1898.

[6] Contreras EM, Rivero SM, García ER, et al. Specific hypertension smartphone application to improve medication adherence in hypertension: a cluster—randomized trial[J]. Curr Med Res Opin， 2019， 35（1）： 167-173.

[7] Wang JG, Li Y, Chia YC, et al. Telemedicine in the management of hypertension: evolving technological platforms for blood pressure telemonitoring[J]. J Clin Hypertens (Greenwich)， 2021， 23（3）： 435-439.

[8] 张玉芬, 陈鹏 . 多维协同护理模式对年轻原发性高血压患者血压管理的影响[J]. 新疆医学， 2025， 55（3）： 361-363.

[9] 宁文奇, 李鼎, 杨丽萍, 等 . 沈阳市住院高血压患者用药依从性分析[J]. 中国公共卫生， 2024， 40（12）： 1511-1514.

[10] 夏阳, 王庆航, 周碧蓉 . 智慧化高血压远程管理模式的实例分析[J]. 临床心血管病杂志， 2024， 40（4）： 323-328.

[11] 方芳, 董晓慧, 范秀丛, 等 . 药学咨询门诊中高血压患者的用药依从性及影响因素分析[J]. 中国药房， 2024， 35（10）： 1276-1279.

[12] 韩泰森, 翟琛琛, 罗震寰, 等 . 中国部分地区高血压患者用药依从性变化的影响因素分析[J]. 医学新知， 2021， 31（2）： 81-87.

[13] Morisky DE, Green LW, Levine DM . Concurrent and predictive validity of a self—reported measure of medication adherence[J]. Med Care， 1986， 24（1）： 67-74.

[14] 侯凯旋, 闫素英 . 慢病患者药物依从性量表的研究[J]. 中国医院药学杂志， 2018， 38（2）： 192-196.

[15] 李孟野, 毕丽岩 . 高血压患者服药依从性的评估方法[J]. 中华高血压杂志， 2023， 31（2）： 171-176.

[16] 张丽琼, 蔡乐 . 高血压服药依从性及其影响因素研究现状[J]. 中华高血压杂志， 2020， 28（1）： 25-29.

[17] 袁旻青 . 基于新媒体的健康促进模式在社区慢性病管理中的应用[J]. 实用临床医药杂志， 2018， 22（23）： 147-150.

[18] 卞伟康, 张代民, 蒋孝馨, 等 . 人工智能在心血管病诊疗中的应用[J]. 中华高血压杂志， 2020， 28（2）： 124-131.

[19] NCD Risk Factor Collaboration (NCD—RisC) . Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population—representative studies with 104 million participants[J]. Lancet， 2021， 398（10304）： 957-980.

[20] World Health Organization . (2025). Global report on hypertension 2025: an unequal burden[EB/OL]. (2026—01—08)[2026—02—04]. https://www.who.int/publications/i/item/9789240115569.

[21] Lee EKP, Poon P, Yip BHK, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta—analysis involving 27 million patients[J]. J Am Heart Assoc， 2022， 11（17）： e026582.

[22] Shaw R, Bosworth HB . Baseline medication adherence and blood pressure in a 24—month longitudinal hypertension study[J]. J Clin Nurs， 2012， 21（9/10）： 1401-1406.

[23] Lee H, Yano Y, Jemma Cho SM, et al. Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension[J]. Hypertension， 2021， 77（4）： 1341-1349.

[24] Kim S, Shin DW, Yun JM, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications[J]. Hypertension， 2016， 67（3）： 506-512.

[25] Mennini FS, Marcellusi A, von der Schulenburg JM, et al. Cost of poor adherence to anti—hypertensive therapy in five European countries[J]. Eur J Health Econ， 2015， 16（1）： 65-72.

[26] Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications[J]. Br J Clin Pharmacol， 2012， 73（5）： 691-705.

[27] Burnier M. Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug adherence[J]. Front Pharmacol， 2018， 9： 1540.

[28] Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension[J]. J Hypertens， 2023， 41（12）： 1874-2071.

[29] Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing[J]. Hypertension， 2022， 79（1）： 12-23.

[30] Meddings J, Kerr EA, Heisler M, et al. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss[J]. BMC Health Serv Res， 2012， 12： 270.

[31] Burnier M, Persu A, Azizi M, et al. Patient perspectives on treatment adherence in hypertension: preliminary results of an ESH survey in five countries[J]. J Hypertens, 2022, 40(Suppl 1): e61.

[32] Bourque G, Ilin JV, Ruzicka M, et al. Nonadherence is common in patients with apparent resistant hypertension: a systematic review and meta—analysis[J]. Am J Hypertens， 2023， 36（7）： 394-403.

[33] Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association[J]. Hypertension， 2022， 79（1）： e1-e14.

[34] Sayer M, Webb DJ, Dhaun N . Novel pharmacological approaches to lowering blood pressure and managing hypertension[J]. Nat Rev Cardiol， 2025， 22（9）： 649-663.

[35] Modena MG, Lodi E . The occurrence of drug—induced side effects in women and men with arterial hypertension and comorbidities[J]. Kardiol Pol， 2022， 80（11）： 1068-1069.

[36] Gerdts E, Sudano I, Brouwers S, et al. Sex differences in arterial hypertension[J]. Eur Heart J， 2022， 43（46）： 4777-4788.

[37] Ali DH, Kiliç B, Hart HE, et al. Therapeutic inertia in the management of hypertension in primary care[J]. J Hypertens， 2021， 39（6）： 1238-1245.

[38] Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence[J]. Blood Press， 2021， 30（5）： 282-290.

[39] Schmieder RE, Wassmann S, Predel HG, et al. Improved persistence to medication, decreased cardiovascular events and reduced all—cause mortality in hypertensive patients with use of single—pill combinations: results from the START—study[J]. Hypertension， 2023， 80（5）： 1127-1135.

[40] Parati G, Stergiou GS, Biol G, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on blood pressure monitoring and cardiovascular variability of the European Society of Hypertension[J]. J Hypertens， 2021， 39（9）： 1742-1767.

[41] Piña IL, Dipalo KE, Brown MT, et al. Medication adherence: importance, issues and policy: a policy statement from the American Heart Association[J]. Prog Cardiovasc Dis， 2021， 64： 111-120.

[42] Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Hypertension， 2025， 82（10）： e212-e316.

[43] Kishore SP, Kocher R . The hypertension control paradox — why is America stuck?[J]. N Engl J Med， 2026， 394（5）： 417-420.

[44] Lauder L, Weber T, Bòhm M, et al. European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice[J]. Nat Rev Cardiol， 2025， 22（9）： 675-688.

[45] Ohya Y, Sakima A, Arima H, et al. Key highlights of the Japanese Society of Hypertension guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)[J]. Hypertens Res， 2025， 48（10）： 2500-2511.

[46] Varzideh F, Mone P, Kansakar U, et al. Artificial intelligence in cardiovascular medicine: focus on hypertension[J]. Hypertension， 2026， 83（6）： e26094.